Trials / Completed
CompletedNCT02591095
A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Centre Francois Baclesse · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
ABT-263 as single agent in women with platinum resistant/refractory recurrent ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-263 |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2017-04-01
- Completion
- 2019-03-01
- First posted
- 2015-10-29
- Last updated
- 2019-03-19
Locations
16 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02591095. Inclusion in this directory is not an endorsement.